Baricitinib

Definition

An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.

Also known as 3-Azetidineacetonitrile, 1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-, BARICITINIB, INCB 028050, INCB028050, JAK inhibitors: baricitinib, LY 3009104, LY-3009104, LY3009104, Olumiant — per NCIT

Also identified as

• ATC L04AF02 per RXNORM
• NCIT NCIT:C127012 per NCIT
• SCTID 726518002 per RXNORM
• SCTID 763701005 per RXNORM
• UNII ISP4442I3Y per RXNORM

Indications

Organ Effects

3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.